Our findings from patients and cell lines support our hypothesis and the newly identified JAK3-INSL3 fusion may be an oncogenic event in MF/SS CTCL. This evidence concerns the gene JAK3 and primary cutaneous T-cell non-Hodgkin lymphoma.